Abstract
LY248686 is an inhibitor of serotonin (5-hydroxytryptamine; 5-HT) and norepinephrine (NE) uptake in synaptosomal preparations of hypothalamus and cerebral cortex, and 5-HT uptake in human blood platelets, with inhibitor constants near nanomolar concentrations. Upon administration to rats 1 hour before sacrifice, LY248686 caused dose-dependent and parallel decreases of 5-HT and NE uptake in hypothalamus homogenates ex vivo. LY248686 is a positive enantiomer and was slightly more potent than its negative isomer, LY248685, as an inhibitor of 5-HT uptake. Both isomers were only weak inhibitors of dopamine (DA) uptake in striatal synaptosomes. The inhibitory effects on 5-HT and NE uptake after a single administration of LY248686 followed similar time courses and simultaneously persisted for as long as 6 hours. LY248686 in vivo could effectively antagonize the p-chloroamphetamine-induced decreases of 5-HT uptake and levels of 5-HT and 5-hydroxyindoleacetic acid in cerebral cortex, and block the accumulation of 14C-NE in rat hearts. In food deprived rats, LY248686 suppressed food intake synergistically with 5-hydroxytryptophan, a precursor amino acid of 5-HT. Because of its lack of affinity for receptors of 5-HT, NE, DA, acetylcholine, histamine and naloxone, and its ability to inhibit 5-HT and NE uptake simultaneously, LY248686 has a favorable pharmacological profile as a potential antidepressant drug.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wong, D., Bymaster, F., Mayle, D. et al. LY248686, A New Inhibitor of Serotonin and Norepinephrine Uptake. Neuropsychopharmacol 8, 23–33 (1993). https://doi.org/10.1038/npp.1993.4
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/npp.1993.4
Keywords
This article is cited by
-
What pharmacological interventions are effective in binge-eating disorder? Insights from a critical evaluation of the evidence from clinical trials
International Journal of Obesity (2022)
-
Pharmacotherapy for Small Fiber Neuropathy
Current Treatment Options in Neurology (2020)
-
Duloxetine, dual serotonin and norepinephrine reuptake inhibitor, versus paroxetine, selective serotonin reuptake inhibitor, in the treatment for premature ejaculation
International Urology and Nephrology (2015)
-
Acute and subacute effects of the selective serotonin–noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels
Naunyn-Schmiedeberg's Archives of Pharmacology (2013)
-
Duloxetine
Drugs & Aging (2013)